Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing, PLoS One, vol.6, p.20294, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00799650
, Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.102-112, 2014.
Trends in survival for patients with metastatic soft-tissue sarcoma, Cancer, vol.117, pp.1049-1054, 2011. ,
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study, J Clin Oncol, vol.29, pp.2528-2533, 2011. ,
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Oncol, vol.17, pp.1732-1742, 2016. ,
Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study, Sarcoma, p.740279, 2012. ,
Health-related quality-of-life results from PALETTE : a randomized, doubleblind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease progressed during or after prior chemotherapy-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Global Network study (EORTC 62072), Cancer, vol.121, pp.2933-2941, 2015. ,
Symptom burden, survival and palliative care in advanced soft tissue sarcoma, Sarcoma, p.325189, 2011. ,
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-a, Br J Cancer, vol.106, pp.1587-1590, 2012. ,
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma, Cancer, vol.122, pp.1108-1115, 2016. ,
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind placebo-controlled phase 3 trial, Lancet, vol.379, pp.1879-1886, 2012. ,
Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom, Sarcoma, p.863056, 2013. ,
Elicitation of health state utilities in soft tissue sarcoma, Qual Life Res, vol.22, pp.1697-1706, 2013. ,